Kyle Diamantas, serving as acting FDA commissioner since Marty Makary's May 2026 resignation, leads named contenders in trader consensus, yet the near-equal probability assigned to no announcement by December 31 underscores the White House's ongoing candidate review and Senate confirmation process. Multiple individuals remain under consideration, with procedural vetting, potential midterms timing pressures, and the need for bipartisan support in a closely divided Senate contributing to the tight spread among options. An official nomination or public statements from administration officials could quickly shift probabilities, while delays in hearings or disputes over qualifications would likely sustain uncertainty around a permanent appointment.